ASM
DMAAR

ATW SPAC Management’s Drugs Made In America Acquisition Corp Rights DMAAR Stock Holding History

ATW SPAC Management’s Portfolio DMAAR Stock Details DMAAR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		$124K Hold
570,000
– – 0.16% 60
2025
Q2 		$68.5K Hold
570,000
– – 0.1% 47
2025
Q1 		$74.1K Buy
+570,000
New +$80K 0.12% 32

Other funds holding DMAAR

RCM
Radcliffe Capital Management Bala Cynwyd, Pennsylvania $1.33B AUM 1.18% 1-Year Est. Return
PAMP
Polar Asset Management Partners Toronto, Ontario, Canada $5.01B AUM 35.27% 1-Year Est. Return
Hudson Bay Capital Management
Hudson Bay Capital Management Stamford, Connecticut $29B AUM 30.2% 1-Year Est. Return
HCI
Harraden Circle Investments New York $499M AUM 24.03% 1-Year Est. Return
Toronto Dominion Bank
Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $69.7B AUM 40.86% 1-Year Est. Return
HCM
Highbridge Capital Management New York $3.09B AUM 31.19% 1-Year Est. Return
AC
Aristeia Capital Greenwich, Connecticut $4.82B AUM 24.94% 1-Year Est. Return
MP
Mangrove Partners Greenwich, Connecticut $1.24B AUM 41.74% 1-Year Est. Return
LA
Linden Advisors New York $17.9B AUM 1.72% 1-Year Est. Return
CS
Clear Street New York $24.6B AUM 56.26% 1-Year Est. Return

ATW SPAC Management's DMAAR Position: Q3 2025 in Review

ATW SPAC Management held its Drugs Made In America Acquisition Corp Rights (DMAAR) position steady in Q3 2025 at 570,000 shares worth $124K. The position accounts for 0.16% of the portfolio, ranked #60.

ATW SPAC Management first reported a position in DMAAR in Q1 2025 and has held it in 3 quarters since. 32 funds tracked by Wall St. Rank hold DMAAR as of Q3 2025.

  • ATW SPAC Management held 570,000 shares of Drugs Made In America Acquisition Corp Rights worth $124K as of Q3 2025.
  • ATW SPAC Management left its Drugs Made In America Acquisition Corp Rights share count unchanged in Q3 2025.
  • Drugs Made In America Acquisition Corp Rights made up 0.16% of ATW SPAC Management's portfolio in Q3 2025, its #60 holding.
  • ATW SPAC Management first reported a position in Drugs Made In America Acquisition Corp Rights in Q1 2025 and has held it in 3 quarters since.
  • 32 funds tracked by Wall St. Rank held Drugs Made In America Acquisition Corp Rights as of Q3 2025.

Based on ATW SPAC Management's 13F filing for Q3 2025, filed 12 Nov 2025.